Biopharmaceutical firm Immunomedics said that it intends to offer shares of its common stock in an underwritten public offering.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, according to Immunomedics. Oppenheimer and Cowen are acting as joint book-running managers for the proposed offering.
